# US 12,617,858 B2 · Anti-Müllerian hormone receptor 2 antibodies and methods of use > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,617,858 B2 - Document ID: US12617858B2 - Status: Granted - Kind: B2 - Application number: 17/792,195 - Filed: 2021-01-29 - Published: 2023-03-16 - Granted: 2026-05-05 - Earliest claimed: 2020-01-31 - Assignees: The Cleveland Clinic Foundation - Applicants: The Cleveland Clinic Foundation - Inventors: Vincent K. Tuohy; Suparna Mazumder; Justin M. Johnson - Web page: https://patentgrep.com/patent/US12617858B2 ## CPC - C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)} - A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} - A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants} - A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants - A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 35/00: Antineoplastic agents - A61P 37/04: Immunostimulants - A61K 2039/505: {comprising antibodies} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59} - A61K 2039/55583: {Polysaccharides} - C07K 2317/21: from primates, e.g. man - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation - C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC] - C07K 2317/734: Complement-dependent cytotoxicity [CDC] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2317/77: Internalization into the cell - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Provided herein are anti-Anti-Müllerian Hormone Receptor 2 (AMHR2) antibodies and methods of using such antibodies, for example, in the treatment of cancer. ## Claims ### Claim 1 An isolated antibody, wherein said antibody comprises a heavy chain comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and a light chain comprising a variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein a) CDR-H1 comprises the sequence shown in SEQ ID NO: 1, b) CDR-H2 comprises the sequence shown in SEQ ID NO: 2, c) CDR-H3 comprises the sequence shown in SEQ ID NO: 3, d) CDR-L1 comprises the sequence shown in SEQ ID NO: 4, e) CDR-L2 comprises the sequence shown in SEQ ID NO: 5, and f) CDR-L3 comprises the sequence shown in SEQ ID NO: 6. ### Claim 2 (depends on 1) The isolated antibody of claim 1, wherein the VH chain sequence comprises the sequence shown in SEQ ID NO: 7. ### Claim 3 (depends on 1) The isolated antibody of claim 1, wherein the VL chain sequence comprises the sequence show in SEQ ID NO: 8. ### Claim 4 (depends on 1) The isolated antibody of claim 1, wherein the antibody is a humanized or chimeric antibody. ### Claim 5 (depends on 1) The isolated antibody of claim 1, wherein the antibody is a monoclonal antibody. ### Claim 6 (depends on 1) A method of treating cancer in a subject in need thereof, comprising administering to the subject the anti-AMHR2 antibody of claim 1, wherein said subject has an AMHR2-expressing cancer. ### Claim 7 (depends on 6) The method of claim 6, wherein the antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) activity, antibody-mediated cellular phagocytosis (ADCP) activity, and/or complement-dependent cytotoxicity (CDC) activity. ### Claim 8 (depends on 6) The method of claim 6, wherein the subject is human. ### Claim 9 (depends on 6) The method of claim 6, wherein the cancer is a solid cancer. ### Claim 10 (depends on 6) The method of claim 6, wherein the cancer is ovarian cancer. ### Claim 11 (depends on 10) The method of claim 10, wherein the ovarian cancer is stage I, stage IA, stage IB, stage IC, stage II, stage IIA, stage IIB, stage III, stage IIIA1, stage IIIA2, stage IIIB, stage IIIC, stage IV, stage IVA, or stage IVB ovarian cancer. ### Claim 12 (depends on 6) The method of claim 6, wherein the antibody is effective at reducing a cancer volume as compared to the cancer volume prior to administration of the antibody. ### Claim 13 An isolated polynucleotide or set of polynucleotides encoding: a) an antibody that comprises a heavy chain comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and a light chain comprising a variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein: i) CDR-H1 comprises the sequence shown in SEQ ID NO: 1, ii) CDR-H2 comprises the sequence shown in SEQ ID NO: 2, iii) CDR-H3 comprises the sequence shown in SEQ ID NO: 3, iv) CDR-L1 comprises the sequence shown in SEQ ID NO: 4, v) CDR-L2 comprises the sequence shown in SEQ ID NO: 5, and iv) CDR-L3 comprises the sequence shown in SEQ ID NO: 6, b) a VH of said antibody, c) a VL of said antibody, d) a light chain of said antibody, e) a heavy chain of said antibody, or f) an antigen-binding portion of said antibody. ### Claim 14 (depends on 13) The isolated polynucleotide or set of polynucleotides of claim 13, wherein said isolated polynucleotide or set of polynucleotides comprise cDNA. ### Claim 15 (depends on 13) The isolated polynucleotide or set of polynucleotides of claim 13, wherein said isolated polynucleotide encodes said VH of said antibody. ### Claim 16 (depends on 13) The isolated polynucleotide or set of polynucleotides of claim 13, wherein said isolated polynucleotide encodes said VL of said antibody.